BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced it will participate in the 7th annual World Anti-Microbial Resistance Congress (WAMR) taking place on November 8 and 9 in Washington, DC.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced that the U.S. Patent and Trademark Office has issued multiple patents covering composition of matter for the company’s therapeutic product candidate TPST-1495.

Instil Bio, Inc. today announced that company management will participate in two upcoming investor conferences in November: Cowen 5th Annual IO Next Summit Monday, November 15, 2021 Session Time: 4:45 PM – 5:05 PM ET

Fully integrated commercialization model and newly appointed leadership to accelerate U.S. business.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Company has entered into a strategic collaboration with Roche Diagnostics.

Helio Health (“Helio”) and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”) today announced new data at AASLD demonstrating the performance of HelioLiver in detecting early hepatocellular carcinoma (HCC).

Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, announces that the American Journal of Transplantation (“AJT”) has published “Donor-Derived Cell-Free DNA Detects Early Evidence of Graft Injury in Stable Liver Transplant Recipients,” by Josh Levitsky, MD, MS.

Biotech Acquisition Company (Nasdaq: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company based in South San Francisco, Calif., announced today that they have entered into a definitive merger agreement.

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2021, on Monday, November 15, 2021, beginning at 8:00 a.m. ET.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), announced today that the U.S. Food and Drug Administration (FDA) has accepted Seelos’ Investigation New Drug (IND) application to study SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia (SCA).